Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — Q1 2022 Earnings Presentation
16 slides from Expres2ion Biotech Holding Ab's earnings presentation, Jun 9, 2022
Slide 1: Proteins for Life
9th June 2022 H C Andersen Capital Webinar Proteins for Life Q1 2022 Financial Report Bent U. Frandsen, CEO
Slide 2: Disclaimer
Disclaimer This company presentation (the ”Company Presentation”), which is personal to the recipient, is issued by ExpreS2ion Biotech Holding AB (the “Company”). The Company Presentation has been prepared for information purposes only and is not to be relied upon in substitution for the exercise of
Slide 3: Investment Highlights
Investment Highlights Key player in advanced protein sciences, with deep pipeline of novel vaccines addressing high- value markets High-potential pipeline of key focus, backed up by Contract Research Organization (CRO) business, that has generated SEK 60 million since IPO in 2016 Vaccine development
Slide 4: Deep Pipeline for Value Creation
Deep Pipeline for Value Creation Development Progress Pre-clinical DISEASE Project/Target Discovery cGMP / Tox Phase I Phase II Phase III Partner/Funding Pharmacology Coronavirus ABNCoV2/SARS-CoV-2cVLP ABNCoV2/SARS-CoV-2 cVLP I / II PREVENT-nCoV 100% Breast Cancer ES2B-C001/HER2cVLP ES2B-C001/HER2 c
Slide 5: ABNCoV2 COVID-19 Vaccine
CORONAVIRUS ABNCoV2 COVID-19 Vaccine Bavarian Nordic completes the Phase II study, and on path for Phase III study initiation Phase II results confirms ABNCoV2 as universal booster Phase III study planned to start in 2nd quarter of 2022 • Evaluation of ABNCoV2 as a booster vaccine in individuals wit
Slide 6: Partnership with Bavarian Nordic
CORONAVIRUS Partnership with Bavarian Nordic ABNCoV2 is already out-licensed with near-term revenue streams supporting ExpreS2ion AdaptVac receive from Bavarian Nordic ExpreS2ion receive from AdaptVac • EUR 4 million upfront (paid in July 2020) • 34% ownership of AdaptVac • Up to EUR 136 million in
Slide 7: Breast Cancer Overview
BREAST CANCER Breast Cancer Overview The ES2B-C001 vaccine can offer significant benefits compared to current treatment options Monoclonal antibodies are the cornerstone of treatment Serious drawbacks exist with these therapies2 for HER2+ breast cancer (>USD 11bn sales)1 • Resistance to monoclonal a
Slide 8: ES2B-C001 Preclinical Proof-of-Concept (I)
BREAST CANCER ES2B-C001 Preclinical Proof-of-Concept (I) ES2B-C001 has demonstrated proof-of-concept Effectively inhibited tumor development in FVB mice Prevented tumor development in delta16 HER2 tg mice Tumor growth in FVB mice (HER2-intolerant) ES2B-C001 with adjuvant (n=20) Control (n = 10) Untr
Slide 9: ES2B-C001 Preclinical Proof-of-Concept (II)
BREAST CANCER ES2B-C001 Preclinical Proof-of-Concept (II) ES2B-C001 has demonstrated proof-of-concept Overcomes trastuzumab-resistance of tumors in vitro Inhibited tumor development in delta16 HER2 tg mice Trastuzumab-sensitive cells Trastuzumab-resistant cells Lung metastasis development in Delta 1
Slide 10: Advancing Towards Key Catalysts
Advancing Towards Key Catalysts 2022 2023 2024 CORONAVIRUS (ABNCoV2) BN Phase II BN Phase II BN Phase III BN Phase III BN ready for study initiation study readout study initiation initial readout market launch (Q3’21) H1 2022 H1 2022 H2 2022 (subject to regulatory approval) BREAST CANCER (ES2B-C001)
Slide 11: Management Team
Management Team >200 years of professional skills and experience from the life sciences industry Management Board of Directors • Bent U. Frandsen, Chief Executive Officer • Dr. Martin R. Jensen, Chairman & Co-founder • Keith Alexander, Chief Financial Officer • Dr. Allan Rosetzsky, Member of the Boa
Slide 12: Q1 2022 Financial Results
Q1 2022 Financial Results Proteins for Life
Slide 13: Income Statement, 2019-2022 Quarterly
FINANCE Income Statement, 2019-2022 Quarterly Revenues, SEK ‘000s Operating profit/loss, SEK ‘000s 6.000 1Q19 2Q19 3Q19 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 0 5.000 -3.000 4.000 -6.000 3.000 -9.000 2.000 -12.000 1.000 -15.000 0 1Q19 2Q19 3Q19 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 4Q21
Slide 14: Cash Balance, 2019-2022 Quarterly
FINANCE 1 Cash Balance , 2019-2022 Quarterly SEK millions 160 142 139 140 125 120 107 108 100 83 80 60 40 30 20 10 13 5 3 5 6 0 1Q19 2Q19 3Q19 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 1 For Q4 2021 and Q1 2022, the cash balance combines funds on the Company’s SKAT account (interest-free tax
Slide 15: Rights Issue Completed Successfully
FINANCE Rights Issue Completed Successfully • Fully guaranteed new share issue of a maximum of 5,841,256 shares with preferential rights for the Company's existing shareholders completed on 5th May 2022 • The subscription price in the Rights Issue was set at SEK 12.50 • A total of 4,966,355 new shar
Slide 16: Thank you!
Thank you! Contact: info@expreS2ionbio.com Proteins for Life
ExpreS2ion Biotech Holding — Q1 2022 Earnings Presentation on 6ix